Highlights from asco gu 2017
-
Upload
mohamed-abdulla -
Category
Health & Medicine
-
view
281 -
download
0
Transcript of Highlights from asco gu 2017
![Page 1: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/1.jpg)
Prostate Cancer“Highlights from ASCO GU – 2017”
Mohamed Abdulla M.D.
Prof. of Clinical Oncology
Cairo University
Astellas Astellas Symposium02/04/2017Grand Nile Tower
![Page 2: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/2.jpg)
Member of Advisory Board, Consultant, and Speaker for:
• Amgen, Astellas, AstraZeneca, Hoffman la Roche, Janssen Cilag, Merck Serono, Novartis, Pfizer, Mundipharma, MSD
Speaker Disclosures:
![Page 3: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/3.jpg)
Outline:
1. Disease demographics and screening.
![Page 4: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/4.jpg)
Demographics of Prostate Cancer:Metastatic Disease at Presentation:
Gilbert Welch et al. NEGM. 2015;373:1685-1687
50%
![Page 5: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/5.jpg)
Demographics of Prostate Cancer:Changes in Mortality Rates:
Kelly et al. EUROPEAN UROLOGY 71 (2017) 195–201
![Page 6: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/6.jpg)
Demographic: Context
![Page 7: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/7.jpg)
Demographic: Metastases
![Page 8: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/8.jpg)
Demographics & USPSTF
![Page 9: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/9.jpg)
Demographics & USPSTF
![Page 10: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/10.jpg)
Screening: PLCO
![Page 11: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/11.jpg)
Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
![Page 12: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/12.jpg)
Pathology - Classification
![Page 13: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/13.jpg)
Pathology - Classification
![Page 14: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/14.jpg)
Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
![Page 15: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/15.jpg)
Localized disease - Treatment
![Page 16: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/16.jpg)
Localized disease - Treatment
![Page 17: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/17.jpg)
Localized disease - Treatment
![Page 18: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/18.jpg)
Localized disease - Treatment
![Page 19: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/19.jpg)
Localized disease - Treatment
![Page 20: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/20.jpg)
Localized disease – Secondary Ca
![Page 21: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/21.jpg)
Localized disease - Surgery
![Page 22: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/22.jpg)
Localized disease - Surgery
![Page 23: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/23.jpg)
Localized disease - Surgery
![Page 24: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/24.jpg)
Localized disease - Surgery
![Page 25: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/25.jpg)
Localized disease - Radiation
![Page 26: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/26.jpg)
Localized disease - Radiation
![Page 27: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/27.jpg)
Localized disease - Radiation
![Page 28: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/28.jpg)
Salvage Radiotherapy: GETUG-AFU 16
![Page 29: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/29.jpg)
Salvage Radiotherapy: GETUG-AFU 16
![Page 30: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/30.jpg)
Salvage Radiotherapy: RTOG 9601
![Page 31: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/31.jpg)
Salvage Radiotherapy: RTOG 9601
![Page 32: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/32.jpg)
Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
4. Metastatic Disease: Treatment.
![Page 33: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/33.jpg)
Metastatic disease: Stampede
![Page 34: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/34.jpg)
Metastatic disease: Stampede
![Page 35: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/35.jpg)
Metastatic disease: Stampede
![Page 36: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/36.jpg)
Metastatic disease: Docetaxol
![Page 37: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/37.jpg)
Metastatic disease: Docetaxol
![Page 38: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/38.jpg)
Metastatic disease: TERRAIN RCT
![Page 39: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/39.jpg)
Metastatic disease: STRIVE RCT
![Page 40: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/40.jpg)
Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
4. Metastatic Disease: Treatment.
5. DNA Repair Genes.
![Page 41: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/41.jpg)
Slide 75
![Page 42: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/42.jpg)
TOPARP Phase 2 Trial:
Mateo etl. N Engl J Med.2015:373;18.
![Page 43: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/43.jpg)
DNA Repair & Metastatic PCa
![Page 44: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/44.jpg)
DNA Repair & Metastatic PCa
![Page 45: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/45.jpg)
Outline:
1. Disease demographics and screening.
2. Pathology – Classification.
3. Localized Disease: Treatment.
4. Metastatic Disease: Treatment.
5. DNA Repair Genes.
6. Intrinsic Subtypes of Prostate Cancer.
![Page 46: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/46.jpg)
Introduction
![Page 47: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/47.jpg)
PAM50 clustering readily identifies luminal (A & B) and basal subtypes in prostate cancer
![Page 48: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/48.jpg)
Luminal B prostate cancers have worse outcomes compared to Luminal A or Basal subtypes
![Page 49: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/49.jpg)
Multivariable analysis for metastatic progression
![Page 50: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/50.jpg)
Different biological pathways are up- or down-regulated in luminal versus basal subtypes<br />
![Page 51: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/51.jpg)
Does subtype predict response to ADT?
![Page 52: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/52.jpg)
Which patients should receive androgen deprivation early in the course of recurrence?
![Page 53: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/53.jpg)
Which patients should receive androgen deprivation early in the course of recurrence?
![Page 54: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/54.jpg)
Not all patients benefit from the addition of anti-androgen therapy to salvage radiotherapy
![Page 55: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/55.jpg)
The next step: Molecular stratification
![Page 56: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/56.jpg)
Conclusions
![Page 57: Highlights from asco gu 2017](https://reader031.fdocuments.in/reader031/viewer/2022021816/58ed9d9a1a28ab3e738b46d3/html5/thumbnails/57.jpg)
Thank You